{"id":739557,"date":"2025-04-15T10:52:01","date_gmt":"2025-04-15T10:52:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=739557"},"modified":"2025-04-15T10:52:01","modified_gmt":"2025-04-15T10:52:01","slug":"myasthenia-gravis-pipeline-2025-comprehensive-clinical-trials-and-therapies-analysis-with-key-moa-and-roa-insights-alpine-immune-science-toleranzia-cabaletta-bio-rallybio-alexion-pharma","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/myasthenia-gravis-pipeline-2025-comprehensive-clinical-trials-and-therapies-analysis-with-key-moa-and-roa-insights-alpine-immune-science-toleranzia-cabaletta-bio-rallybio-alexion-pharma_739557.html","title":{"rendered":"Myasthenia Gravis Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights | Alpine Immune Science, Toleranzia, Cabaletta Bio, Rallybio, Alexion Pharma"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/upload\/2025\/04\/1744665222.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Myasthenia Gravis Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights | Alpine Immune Science, Toleranzia, Cabaletta Bio, Rallybio, Alexion Pharma\" src=\"https:\/\/www.abnewswire.com\/upload\/2025\/04\/1744665222.jpg\" alt=\"Myasthenia Gravis Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights | Alpine Immune Science, Toleranzia, Cabaletta Bio, Rallybio, Alexion Pharma\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">(Las Vegas, Nevada, United States)  As per DelveInsight\u2019s assessment, globally, Myasthenia Gravis pipeline constitutes 20+ key companies continuously working towards developing 22+ Myasthenia Gravis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.<\/div>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">The Myasthenia Gravis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>&ldquo;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/myasthenia-gravis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Myasthenia Gravis Pipeline Insight, 20<\/a><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/myasthenia-gravis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">25<\/a>&#8220;<\/strong> report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Myasthenia Gravis Market.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key takeaways from the Myasthenia Gravis Pipeline Report: <\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Companies across the globe are diligently working toward developing novel Myasthenia Gravis treatment therapies with a considerable amount of success over the years.<\/p>\n<\/li>\n<li>\n<p>Myasthenia Gravis companies working in the treatment market are <strong>Alpine Immune Science, Toleranzia, Cabaletta Bio, Rallybio, Alexion Pharmaceuticals, Takeda, Cartesian Therapeutics, RemeGen, Horizon Therapeutics, and others<\/strong>, are developing therapies for the Myasthenia Gravis treatment<\/p>\n<\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Emerging Myasthenia Gravis therapies in the different phases of clinical trials are- <strong>Povetacicept, TOL 2, MuSK-CAART, RLYB116, ALXN2050, TAK-079, Descartes-08, Telitacicept, Inebilizumab, and others<\/strong> are expected to have a significant impact on the Myasthenia Gravis market in the coming years.<\/p>\n<\/li>\n<li>\n<p><strong>In April 2025,<\/strong> Remarkable findings from the Phase 3 clinical trial (NCT05737160) assessing the safety and effectiveness of Telitacicept (also known as RC18; brand name: \u6cf0\u7231&reg;) in patients with generalized myasthenia gravis (gMG) were showcased during the Late-Breaking Science Session at the 2025 American Academy of Neurology (AAN) Annual Meeting held in San Diego, California.<\/p>\n<\/li>\n<li>\n<p><strong>In January 2025, Cartesian Therapeutics, Inc. (NASDAQ: RNAC),<\/strong> a clinical-stage biotechnology firm advancing mRNA cell therapies for autoimmune disorders, announced that it has received written agreement from the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process. This agreement pertains to the overall design of the upcoming Phase 3 AURORA trial evaluating Descartes-08, the company&rsquo;s lead mRNA cell therapy candidate, for treating myasthenia gravis (MG). The SPA confirms that the FDA finds the proposed trial design acceptable to potentially support a future Biologics License Application for Descartes-08, pending successful trial results.<\/p>\n<\/li>\n<li>\n<p><strong>In June 2024, Johnson &amp; Johnson (NYSE: JNJ)<\/strong> announced positive results from the Phase 3 Vivacity-Myasthenia Gravis3 study of nipocalimab in patients with generalized myasthenia gravis (gMyasthenia Gravis). Patients receiving nipocalimab alongside standard care (SOC) showed superior improvement over those receiving placebo plus SOC, as measured by the primary endpoint of the Myasthenia Gravis-ADL score improvement from baseline over 24 weeks. These findings are part of a presentation and one of eight abstracts Johnson &amp; Johnson will present at the European Academy of Neurology (EAN) 2024 Congress and will be included in regulatory submissions later this year.<\/p>\n<\/li>\n<li>\n<p><strong>In January 2024, Cartesian Therapeutics<\/strong>&rsquo; Descartes-08, an investigational autologous mRNA-engineered chimeric antigen receptor T-cell (CAR-T) therapy for autoimmune diseases like myasthenia gravis (Myasthenia Gravis), has shown clinically significant improvements in the phase 2a part of a clinical trial (NCT04146051) for Myasthenia Gravis. All 7 patients in the phase 2a portion, treated with a single infusion of Descartes-08 weekly for 6 weeks, demonstrated substantial and lasting clinical improvements in Myasthenia Gravis Composite, Myasthenia Gravis Activities of Daily Living, Quantitative Myasthenia Gravis scores, and Quality of Life 15-revised assessments at 9 months post-treatment.<\/p>\n<\/li>\n<li>\n<p><strong>In January 2024, RYSTIGGO&reg; (rozanolixizumab-noli)<\/strong> is a specialized treatment for adults with generalized myasthenia gravis (gMyasthenia Gravis) who test positive for anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibodies. Created by the Belgian biopharmaceutical company UCB, RYSTIGGO is provided in a single-dose vial containing 280mg\/2ml (140mg\/ml) of a colorless to light brownish-yellow solution, intended for subcutaneous injection.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Myasthenia Gravis Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Myasthenia Gravis is a chronic autoimmune neuromuscular disorder characterized by weakness and rapid fatigue of voluntary muscles. The name, which translates to &#8220;grave muscle weakness,&#8221; reflects the primary symptom of the condition. Myasthenia Gravis occurs when the immune system produces antibodies that interfere with the communication between nerves and muscles.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get a Free Sample PDF Report to know more about Myasthenia Gravis Pipeline Therapeutic Assessment-<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/myasthenia-gravis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">https:\/\/www.delveinsight.com\/report-store\/myasthenia-gravis-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Emerging Myasthenia Gravis Drugs Under Different Phases of Clinical Development Include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p><strong>Povetacicept:<\/strong> Alpine Immune Science<\/p>\n<\/li>\n<li>\n<p><strong>TOL 2<\/strong>: Toleranzia<\/p>\n<\/li>\n<li>\n<p><strong>MuSK-CAART:<\/strong> Cabaletta Bio<\/p>\n<\/li>\n<li>\n<p><strong>RLYB116:<\/strong> Rallybio<\/p>\n<\/li>\n<li>\n<p><strong>ALXN2050:<\/strong> Alexion Pharmaceuticals<\/p>\n<\/li>\n<li>\n<p><strong>TAK-079:<\/strong> Takeda<\/p>\n<\/li>\n<li>\n<p><strong>Descartes-08: <\/strong>Cartesian Therapeutics<\/p>\n<\/li>\n<li>\n<p><strong>Telitacicept:<\/strong> RemeGen<\/p>\n<\/li>\n<li>\n<p><strong>Inebilizumab:<\/strong> Horizon Therapeutics<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Myasthenia Gravis Route of Administration<\/strong><\/p>\n<p style=\"text-align: justify;\">Myasthenia Gravis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Infusion<\/p>\n<\/li>\n<li>\n<p>Intradermal<\/p>\n<\/li>\n<li>\n<p>Intramuscular<\/p>\n<\/li>\n<li>\n<p>Intranasal<\/p>\n<\/li>\n<li>\n<p>Intravaginal<\/p>\n<\/li>\n<li>\n<p>Oral<\/p>\n<\/li>\n<li>\n<p>Parenteral<\/p>\n<\/li>\n<li>\n<p>Subcutaneous<\/p>\n<\/li>\n<li>\n<p>Topical<\/p>\n<\/li>\n<li>\n<p>Molecule Type<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Myasthenia Gravis Molecule Type<\/strong><\/p>\n<p style=\"text-align: justify;\">Myasthenia Gravis Products have been categorized under various Molecule types, such as<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Vaccines<\/p>\n<\/li>\n<li>\n<p>Monoclonal Antibody<\/p>\n<\/li>\n<li>\n<p>Peptides<\/p>\n<\/li>\n<li>\n<p>Polymer<\/p>\n<\/li>\n<li>\n<p>Small molecule<\/p>\n<\/li>\n<li>\n<p>Product Type<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Myasthenia Gravis Pipeline Therapeutics Assessment<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Myasthenia Gravis Assessment by Product Type<\/p>\n<\/li>\n<li>\n<p>Myasthenia Gravis By Stage and Product Type<\/p>\n<\/li>\n<li>\n<p>Myasthenia Gravis Assessment by Route of Administration<\/p>\n<\/li>\n<li>\n<p>Myasthenia Gravis By Stage and Route of Administration<\/p>\n<\/li>\n<li>\n<p>Myasthenia Gravis Assessment by Molecule Type<\/p>\n<\/li>\n<li>\n<p>Myasthenia Gravis by Stage and Molecule Type<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&#8217;s Myasthenia Gravis Report covers around 22+ products under different phases of clinical development like<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Late-stage products (Phase III)<\/p>\n<\/li>\n<li>\n<p>Mid-stage products (Phase II)<\/p>\n<\/li>\n<li>\n<p>Early-stage product (Phase I)<\/p>\n<\/li>\n<li>\n<p>Pre-clinical and Discovery stage candidates<\/p>\n<\/li>\n<li>\n<p>Discontinued &amp; Inactive candidates<\/p>\n<\/li>\n<li>\n<p>Route of Administration<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Further Myasthenia Gravis product details are provided in the report. Download the Myasthenia Gravis pipeline report to learn more about the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/myasthenia-gravis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">emerging Myasthenia Gravis therapies<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key companies in the Myasthenia Gravis Therapeutics Market include:<\/strong><\/p>\n<p style=\"text-align: justify;\">Key companies developing therapies for Myasthenia Gravis are &#8211; <em><strong>CuraVac, Grifols SA, Immunovant, Mitsubishi Tanabe Pharma, Novartis, Alexion Pharmaceutical, Argenx, Astellas Pharma, UCB Pharma, Bausch Health, and others.<\/strong><\/em><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Myasthenia Gravis Pipeline Analysis:<\/strong><\/p>\n<p style=\"text-align: justify;\">The Myasthenia Gravis pipeline report provides insights into<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>The report provides detailed insights about companies that are developing therapies for the treatment of Myasthenia Gravis with aggregate therapies developed by each company for the same.<\/p>\n<\/li>\n<li>\n<p>It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myasthenia Gravis Treatment.<\/p>\n<\/li>\n<li>\n<p>Myasthenia Gravis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li>\n<p>Myasthenia Gravis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.<\/p>\n<\/li>\n<li>\n<p>Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Myasthenia Gravis market.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">The report is built using data and information traced from the researcher&rsquo;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Myasthenia Gravis Pipeline Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Increasing prevalence of Myasthenis gravis, growing awareness regarding the myasthenia gravis diagnosis options, surge in geriatric population with autoimmune disease are some of the important factors that are fueling the Myasthenia Gravis Market.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Myasthenia Gravis Pipeline Market Barriers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>However, limited reimbursement policies, high cost associated with the treatment and other factors are creating obstacles in the Myasthenia Gravis Market growth.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of Myasthenia Gravis Pipeline Drug Insight <\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p><strong>Coverage: Global<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>Key Myasthenia Gravis Companies:<\/strong> Alpine Immune Science, Toleranzia, Cabaletta Bio, Rallybio, Alexion Pharmaceuticals, Takeda, Cartesian Therapeutics, RemeGen, Horizon Therapeutics, and others<\/p>\n<\/li>\n<li>\n<p><strong>Key Myasthenia Gravis Therapies:<\/strong> Povetacicept, TOL 2, MuSK-CAART, RLYB116, ALXN2050, TAK-079, Descartes-08, Telitacicept, Inebilizumab, and others<\/p>\n<\/li>\n<li>\n<p><strong>Myasthenia Gravis Therapeutic Assessment:<\/strong> Myasthenia Gravis current marketed and Myasthenia Gravis emerging therapies<\/p>\n<\/li>\n<li>\n<p><strong>Myasthenia Gravis Market Dynamics: Myasthenia Gravis market drivers and Myasthenia Gravis market barriers <\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Sample PDF Report for <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/myasthenia-gravis-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Myasthenia Gravis Pipeline Assessment and clinical trials<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Myasthenia Gravis Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Myasthenia Gravis Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. Myasthenia Gravis Overview<\/p>\n<p style=\"text-align: justify;\">4. Myasthenia Gravis- Analytical Perspective In-depth Commercial Assessment<\/p>\n<p style=\"text-align: justify;\">5. Myasthenia Gravis Pipeline Therapeutics<\/p>\n<p style=\"text-align: justify;\">6. Myasthenia Gravis Late Stage Products (Phase II\/III)<\/p>\n<p style=\"text-align: justify;\">7. Myasthenia Gravis Mid Stage Products (Phase II)<\/p>\n<p style=\"text-align: justify;\">8. Myasthenia Gravis Early Stage Products (Phase I)<\/p>\n<p style=\"text-align: justify;\">9. Myasthenia Gravis Preclinical Stage Products<\/p>\n<p style=\"text-align: justify;\">10. Myasthenia Gravis Therapeutics Assessment<\/p>\n<p style=\"text-align: justify;\">11. Myasthenia Gravis Inactive Products<\/p>\n<p style=\"text-align: justify;\">12. Company-University Collaborations (Licensing\/Partnering) Analysis<\/p>\n<p style=\"text-align: justify;\">13. Myasthenia Gravis Key Companies<\/p>\n<p style=\"text-align: justify;\">14. Myasthenia Gravis Key Products<\/p>\n<p style=\"text-align: justify;\">15. Myasthenia Gravis Unmet Needs<\/p>\n<p style=\"text-align: justify;\">16 . Myasthenia Gravis Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\">17. Myasthenia Gravis Future Perspectives and Conclusion<\/p>\n<p style=\"text-align: justify;\">18. Myasthenia Gravis Analyst Views<\/p>\n<p style=\"text-align: justify;\">19. Appendix<\/p>\n<p style=\"text-align: justify;\">20. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Gaurav Bora<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=myasthenia-gravis-pipeline-2025-comprehensive-clinical-trials-and-therapies-analysis-with-key-moa-and-roa-insights-alpine-immune-science-toleranzia-cabaletta-bio-rallybio-alexion-pharma\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=myasthenia-gravis-pipeline-2025-comprehensive-clinical-trials-and-therapies-analysis-with-key-moa-and-roa-insights-alpine-immune-science-toleranzia-cabaletta-bio-rallybio-alexion-pharma\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>(Las Vegas, Nevada, United States) As per DelveInsight\u2019s assessment, globally, Myasthenia Gravis pipeline constitutes 20+ key companies continuously working towards developing 22+ Myasthenia Gravis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/myasthenia-gravis-pipeline-2025-comprehensive-clinical-trials-and-therapies-analysis-with-key-moa-and-roa-insights-alpine-immune-science-toleranzia-cabaletta-bio-rallybio-alexion-pharma_739557.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-739557","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/739557","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=739557"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/739557\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=739557"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=739557"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=739557"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}